Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 9/2018

01-09-2018 | Letter to the Editor

Reply to Dereke, J., Hillman, M. “The significance of biomarkers such as FABP4 in gestational diabetes mellitus and the importance of rigorous peer review” Acta Diabetol (2017) 54:885. https://doi.org/10.1007/s00592-017-1026-6

Authors: Hui Ning, Hong Tao, Zhanping Weng, Xingbo Zhao

Published in: Acta Diabetologica | Issue 9/2018

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
Ning H et al (2016) Plasma fatty acid-binding protein 4 (FABP4) as a novel biomarker to predict gestational diabetes mellitus. Acta Diabetol 53(6):891–898CrossRefPubMed
3.
Kralisch S et al (2009) Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus. Eur J Endocrinol 160(1):33–38CrossRefPubMed
4.
Ortega-Senovilla H et al (2011) Gestational diabetes mellitus causes changes in the concentrations of adipocyte fatty acid-binding protein and other adipocytokines in cord blood. Diabetes Care 34(9):2061–2066CrossRefPubMedPubMedCentral
5.
Li YY et al (2015) Increased plasma levels of FABP4 and PTEN is associated with more severe insulin resistance in women with gestational diabetes mellitus. Med Sci Monit 21:426–431CrossRefPubMedPubMedCentral
Metadata
Title
Reply to Dereke, J., Hillman, M. “The significance of biomarkers such as FABP4 in gestational diabetes mellitus and the importance of rigorous peer review” Acta Diabetol (2017) 54:885. https://doi.org/10.1007/s00592-017-1026-6
Authors
Hui Ning
Hong Tao
Zhanping Weng
Xingbo Zhao
Publication date
01-09-2018
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 9/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1178-z

Other articles of this Issue 9/2018

Acta Diabetologica 9/2018 Go to the issue

Original Article

Physical activity during pregnancy is associated with a lower prevalence of gestational diabetes mellitus in Vietnam

Review Article

The post-HAPO situation with gestational diabetes: the bright and dark sides

Letter to the Editor

Can HbA1c combined with fasting plasma glucose help to assess priority for GCK-MODY vs HNF1A-MODY genetic testing?

Original Article

Prevalence and predictors of depression and anxiety in adult patients with type 1 diabetes in tertiary care setting

Original Article

The relationship between sleep and cognitive function in patients with prediabetes and type 2 diabetes

Original Article

Relationship between sleep disturbance and self-care in adults with type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits